alexa An MRNA-based Vaccine Technology For Next Generation Prophylactic Vaccines
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

15th Annual Summit on Vaccines and Immunization
February 20-21, 2017 Berlin, Germany

Susanne Rauch, Lutz J, Lazzaro S, Schmidt K, Petsch B, Baumhof P, Heidenreich H and Fotin-Mleczek M
CureVac, Germany
ScientificTracks Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560.C1.054
In recent years, messenger RNA (mRNA) based technologies have increasingly been applied in vaccine development. Such approaches have utilized mRNA for both therapeutic cancer vaccinations, and for prophylactic vaccines, drawing much attention from industrial and academic fields. RNActive®, an mRNA based vaccination technology, has yielded promising results in the development of vaccines against a variety of viral pathogens such as RSV (respiratory syncytial virus), influenza, rabies, and Ebola virus in several animal models. We have previously shown that intradermal (i.d.) application of RNActive® vaccines is able to confer protection against lethal influenza and rabies virus challenge infection in mice and induces protective levels of functional antibody responses against both viruses in domestic pigs. However, having been optimized for i.d. application, immunological responses upon intramuscular (i.m.) injection of these mRNA vaccine formulations remained less efficient as yet. Here, we describe an alternative formulation of RNActive® vaccines that is able to induce potent immune responses when applied intramuscularly using low doses (μg) of mRNA. Vaccination of mice with this RNActive® formulation encoding for influenza HA (hemagglutinin) or rabies G (glycoprotein) revealed an increase of both humoral and cellular immune responses, analyzed via functional antibody levels and ICS (intracellular cytokine staining) of T cells, respectively, compared to previous RNActive® formulations. Further experiments showed that this new vaccine formulation was able to induce potent and long lasting immune responses against influenza HA as well as high titers of rabies virus neutralizing antibodies in NHPs (non-human primates).

Susanne Rauch works as a Scientist at CureVac where she is involved in the development of mRNA-based prophylactic vaccines. She has been trained as a Postdoc at King’s College London and as a PhD student at University Hospital Heidelberg where her work was focused on “The biology of different viruses such as HIV-1, MLV and herpesviruses.

Email: [email protected]

image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version